Thyroid eye disease occupies an unusual corner of medicine: it begins in the immune system, plays out inside the eye socket, and ends - for many patients - with a carefully staged series of surgeries that must happen in a specific order. That order is not convention. It is physics. Understanding why a thyroid condition does what it does to the orbit, and why fixing it takes the steps it does, makes every part of the treatment timeline make more sense.
Why a Thyroid Condition Ends Up Inside the Eye Socket
The culprit is not the thyroid itself but the autoantibodies that attack it. In Graves' disease, the immune system produces antibodies against the TSH receptor - the docking site thyroid cells use to receive signals from the pituitary. Those antibodies overstimulate the thyroid, driving it to produce too much hormone. So far, that is a thyroid problem.
The eye connection happens because TSH receptors are not exclusive to thyroid tissue. Orbital fibroblasts - the connective tissue cells that fill the fat compartments and surround the muscles inside the bony eye socket - carry the same receptor. When TSH-receptor antibodies reach the orbit, they activate those fibroblasts and trigger a local inflammatory cascade. The cells swell, multiply, and accumulate glycosaminoglycans, gel-like molecules that draw in water. The volume of tissue inside the orbit expands.
The orbit has no room to spare. It is a bony cone with one opening - the front, where the eye sits. Expanding tissue can only go one direction: forward. The eye is physically pushed out of its natural position. That forward displacement is proptosis, and it explains why someone whose thyroid is now medically controlled can still have dramatically altered eyelids and a bulging appearance that has nothing to do with current thyroid hormone levels.
Thyroid eye disease affects roughly 40% of people with Graves' disease - a figure drawn from systematic reviews pooling multiple published studies - and is far more common in women than in men. Most cases are mild. About one in five patients develops moderate-to-severe disease that meaningfully affects vision or daily life, and a small fraction reaches the sight-threatening end of the spectrum.
Active versus Inactive Phase: Why Timing Governs Everything
TED is not a static condition. After onset, it goes through an inflammatory phase during which tissue inside the orbit is actively swelling and changing. This period typically lasts between one and three years. After that, inflammation subsides and the residual damage - stretched eyelid muscles, enlarged extraocular muscles, permanently displaced fat - becomes fixed. The tissue is no longer actively inflamed, but it does not spontaneously remodel either.
This two-phase structure governs the entire treatment timeline. Any elective surgery requires the thyroid to be medically controlled and the eye disease to have been inactive for at least six months before the first operation. Operating during the active phase produces unpredictable results because the anatomy is still shifting. A lid position corrected today may move substantially as inflammation continues to alter the surrounding tissue.
The Clinical Activity Score in Plain Language
Doctors assess whether TED is still in its active inflammatory phase using a tool called the Clinical Activity Score, or CAS. It scores seven observable signs, each worth one point. A score of three or more out of seven indicates active disease. The seven criteria are:
- Spontaneous pain in or behind the eye, not linked to eye movement
- Pain when moving the eyes in any direction
- Swelling of the eyelids
- Redness of the eyelids
- Redness of the conjunctiva, the membrane covering the white of the eye
- Chemosis - swelling and a waterlogged appearance of the conjunctiva
- Inflammation of the caruncle or plica, the small tissue structures in the inner corner of the eye
A patient tracking their own condition between appointments can notice trends. If pain on eye movement disappears, or eyelid redness fades, those are signs the active phase may be winding down. The CAS is not a self-diagnosis tool, but understanding what your doctor is looking at in each visit allows for more meaningful conversations about when the required stable window has genuinely begun.
The Four Main Changes TED Causes Around the Eye
TED produces four main tissue-level changes that a surgeon eventually has to address. They do not occur in isolation - each one compounds the others.
- Eyelid retraction. The upper lid sits too high, exposing white sclera above the iris. This is the most common sign of TED, occurring in roughly 90% of patients. Inflammatory changes stiffen and shorten the levator muscle and its associated Muller's muscle, pulling the lid upward. Lower lid retraction - the lower lid sitting too low - also occurs and causes its own set of problems.
- Proptosis. The eye is physically pushed forward out of the socket by expanding orbital tissue. Even a few millimeters of forward displacement is visible and impairs lid closure.
- Diplopia. Double vision results from fibrosis in the extraocular muscles. When those muscles stiffen, they no longer move in a balanced, coordinated way. The inferior rectus - the muscle that pulls the eye downward - is most commonly affected first.
- Corneal exposure. Proptosis combined with lid retraction means the eye protrudes while the lids cannot fully cover it. The exposed cornea dries. In severe cases, corneal ulceration can threaten sight.
The interplay between these four changes matters for surgery planning. Correcting proptosis by repositioning the eye changes how the lids meet the globe, which changes how the extraocular muscles pull. Every tissue adjustment has downstream effects on the others - which is precisely why correction requires a sequence rather than a single operation.
Medical Treatment Before Surgery: What Teprotumumab Does and Does Not Do
Until 2020, treatment for active TED relied mainly on intravenous steroids and radiotherapy. Neither addressed the underlying biology precisely. Teprotumumab, sold under the brand name Tepezza, received FDA approval in January 2020 as the first drug specifically indicated for TED.
It works by blocking the IGF-1 receptor - the insulin-like growth factor-1 receptor - on orbital fibroblasts. That receptor is part of the same signaling complex that TSH-receptor antibodies activate. Blocking it interrupts the inflammatory cascade at a more targeted point than steroids can reach. In the pivotal Phase 3 trial published in the New England Journal of Medicine, a large majority of treated patients achieved clinically significant proptosis reduction, compared with a small fraction on placebo.
What teprotumumab addresses and what it does not:
- It reduces proptosis during the active inflammatory phase by shrinking inflamed orbital tissue
- It can reduce diplopia if muscle stiffness is driven by active inflammation rather than established fibrosis
- It does not reverse fibrosis - the hardened tissue that persists after the inflammatory phase has ended
- It does not correct eyelid retraction reliably enough to eliminate the need for lid surgery in most moderate-to-severe cases
- It is administered by infusion over several months and is used during the active phase, not as a substitute for surgical correction of established anatomical change
A patient who responds well to teprotumumab may still need orbital decompression afterward - because some proptosis persisted, or because fibrotic changes that preceded treatment still require surgical correction. The drug can narrow the surgical gap. For patients with significant disease, it rarely eliminates it.
Why Three Surgeries in One Fixed Order
This is the part most patient resources skip past. TED correction is not three interchangeable procedures to be scheduled for convenience. It is a mechanical sequence in which each step creates the conditions the next step requires.
The surgical sequence is non-negotiable because each operation changes the physical geometry that the next operation is designed to measure and correct. Reversing the order does not save time - it produces measurements that become invalid the moment the preceding step is performed.
- Orbital decompression first. Removing bone from the orbital walls allows the eye to move backward into the socket, reducing proptosis. This repositioning changes the relationship between the globe and the extraocular muscles - the muscles now pull from a different angle. If strabismus surgery were done before decompression, the surgeon would be correcting an eye muscle imbalance that will shift the moment decompression changes globe position. That correction would be invalid.
- Strabismus surgery second. Once the globe sits in its decompressed position, the muscle imbalance can be accurately measured and corrected. Strabismus surgery may also alter lid position slightly - another reason it must precede lid work rather than follow it.
- Eyelid retraction surgery last. Only after globe position and eye alignment are stable can the surgeon set the lid at the correct height. Lid position is measured in small increments. If either prior step is performed out of order, the lid is set against a target that will subsequently shift.
Orbital Decompression: Walls, Fat, and the Diplopia Trade-off
Orbital decompression creates more space inside the orbit by removing portions of its bony walls - the medial wall toward the nose, the floor, the lateral wall toward the temple, or some combination - and sometimes also removing fat from compartments inside the orbit. Which walls are addressed depends on the degree of proptosis and the surgeon's assessment of the patient's anatomy and risk profile.
More walls opened means greater potential reduction in proptosis, but also greater disruption to the muscle anatomy inside the orbit and greater risk of new or worsened double vision after surgery. This trade-off is one of the central planning decisions in TED surgery.
| Approach | Proptosis reduction | New-onset diplopia risk | Typical indication |
|---|---|---|---|
| Medial wall (1.5-wall) | Modest | Lower than lateral approaches | Mild-to-moderate proptosis |
| Lateral wall (single) | Moderate | Moderate | Moderate proptosis, cosmetic priority |
| Medial plus floor | Moderate-to-high | Higher - floor removal shifts inferior rectus | Significant proptosis with functional impact |
| Three-wall (2.5-wall) | Highest | Highest - planned strabismus surgery expected | Severe proptosis, sight-threatening cases |
New or worsened double vision is a known consequence of orbital decompression, particularly when the floor is removed. This is one reason strabismus surgery follows decompression in the sequence: some of the diplopia that strabismus surgery corrects is itself caused by the decompression, not only by the disease. Planning for strabismus surgery before decompression would mean planning for an eye muscle state that does not yet exist.
Eyelid Retraction Surgery: Lengthening What the Disease Shortened
Upper Lid
Upper eyelid retraction surgery addresses two structures that inflammatory changes have shortened and stiffened: the levator aponeurosis and Muller's muscle, both of which run along the back surface of the lid and attach to the upper tarsal plate. The procedure - called recession - involves surgically releasing and repositioning those attachments so the lid sits lower. With less upward pull, the lid descends to a more natural height over the iris.
The surgeon deliberately aims slightly low during the operation. This is not imprecision - it is intentional. Post-operative swelling elevates the lid temporarily, and the final settled position is higher than the immediate post-operative result. A surgeon who sets the lid exactly at the target height on the table will often end up with an over-corrected, too-high result once the swelling resolves. Aiming slightly low counteracts this predictable shift.
Lower Lid
Lower eyelid retraction is structurally different and generally harder to hold in the corrected position. The lower lid does not have a single dominant retractor analogous to the levator, and soft tissue tends to pull the lid back down over time after simple release alone. For this reason, lower eyelid retraction surgery commonly requires a spacer graft - a segment of tissue placed between the conjunctiva and the lid to physically maintain the corrected height. Surgeons use ear cartilage, hard palate mucosa harvested from the roof of the mouth, or synthetic spacer materials, depending on the amount of correction needed and patient anatomy. The choice of spacer affects the firmness and final contour of the lid.
Recovery: Why This Is Different from Cosmetic Blepharoplasty
Patients who have had cosmetic eyelid surgery before - or who know someone who has - sometimes arrive at TED surgery expecting a similar recovery. The comparison misleads. TED surgery, particularly orbital decompression, involves considerably more swelling and bruising than standard blepharoplasty.
The reason is vascular. Chronic orbital inflammation engorges both the arterial supply and venous drainage around the orbit. By the time a TED patient reaches surgery, the vasculature in the area is far more prominent than it would be in a patient undergoing elective cosmetic lid work. More blood means more operative bleeding, more extensive post-operative bruising, and more fluid accumulation during healing. Patients should expect visible bruising and swelling that would be unusual after routine lid surgery.
Swelling after orbital decompression can take weeks to substantially resolve and several months to fully settle. Lid position in particular should not be assessed as a final result until the tissue has stabilized - which can mean watching an uneven or imperfect-looking result for months before the next planned step. The staged nature of TED correction means patients are often in an intermediate state between procedures for a year or more. Understanding this in advance prevents the common mistake of interpreting a normal post-operative appearance as a surgical problem.
Smoking compounds every stage of this process. Among people with Graves' disease, smokers have a substantially higher rate of proptosis and double vision than non-smokers - the biological reason is that smoking amplifies the same inflammatory signaling that drives orbital tissue expansion. The risk applies to disease severity, to the likelihood of developing TED at all, and to recovery from surgery. Continued smoking after surgery impairs healing and is linked to worse outcomes. Cessation before any treatment begins is not optional guidance. It is a meaningful clinical intervention.
Frequently Asked Questions
Can eyelid surgery begin as soon as the thyroid is under control?
No. Normal thyroid hormone levels are necessary but not sufficient. The eye disease itself must be clinically inactive - as measured by the Clinical Activity Score and physical examination - for at least six months before elective surgery begins. The thyroid and the orbit are on separate inflammatory timelines, and one can be controlled while the other is still active.
Will teprotumumab replace surgery for most TED patients?
Not for patients with moderate-to-severe disease. Teprotumumab addresses active inflammation and can meaningfully reduce proptosis when the disease is still in its inflammatory phase. It does not reverse fibrosis - the permanent structural changes that remain after inflammation subsides - and does not correct eyelid retraction reliably enough to eliminate surgery for patients with significant anatomical change. It narrows the problem; for most affected patients, it does not resolve it entirely.
Why can't all three surgeries be combined into one operation?
Because the result of each operation physically changes what the next one is correcting. Decompression repositions the globe, and that repositioning alters the eye muscle geometry that strabismus surgery measures. Strabismus surgery then changes lid dynamics slightly. Performing all three at once would require correcting a moving target. The sequence is not about staged healing time - it is about dependent measurements that only become valid in order.
Is new double vision after orbital decompression permanent?
Not necessarily. New diplopia following decompression, particularly when the orbital floor is involved, may partially resolve as post-operative swelling subsides. Persistent diplopia is addressed by strabismus surgery, which is already the planned second step in the sequence. This is one reason strabismus surgery follows rather than precedes decompression - some of what it corrects is the direct result of decompression itself.
How long does the full surgical process take from first operation to final result?
For patients who need all three stages, the process from the first operation to the final lid surgery can span a year or more. That timeline accounts for the six-month disease stability requirement before any surgery begins, the healing interval between each stage, and the time needed to confirm stable results before proceeding. Patients should plan for a multi-year commitment from disease onset to completion of surgical correction.
Does quitting smoking help if TED is already established?
Yes, at every stage. The link between smoking and worse TED outcomes reflects ongoing inflammatory drive that smoking continues to amplify - it is not a fixed historical exposure. Cessation reduces ongoing inflammatory activity, improves surgical healing, and is recommended by treating physicians regardless of how long the disease has been present or how far along treatment is.